Clinical Trials (NETs)

Here you will find information on the current clinical trials in this field.

You are here:

Current Clinical Trials (NETs)

CLARINET FORTE

Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide Autogel® 120 mg administered every 28 days”as amended from time to time and incorporated herein by reference

Contact person: Dr. H. Jann

COMPETE

A prospective, randomised, Controled, Open-label, Multicentre phase lll study  to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSIR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)

Contact person: Dr. H. Jann

EVINEC 

Safety and tolerability of Everolimus as second-line treatment in poorly differenciated neuroendocrine carcinoma/neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3- an investigational initialled Phase II study/EVINEC

Contact person: Dr. H. Jann

NETTER-I

A multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive midgut carcinoid tumours

Contact person: Dr. H. Jann

SEQTOR

Randomized open label study to compare the efficacy and safety of Everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by Everolimus upon progression, in advanced progressive pNETs

Contact person: Dr. H. Jann